about
Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment.Single-incision sling system as primary treatment of female stress urinary incontinence: prospective 12 months data from a single institution.Coffee and gastric cancer: systematic review and meta-analysis.Model-based patterns in prostate cancer mortality worldwideErectile dysfunction in obstructive sleep apnea syndrome--prevalence and determinants.How do cognitive and axial motor signs correlate in Parkinson's disease? A 6-year prospective study.Urinary neurotrophic factors in healthy individuals and patients with overactive bladder.Does baseline total testosterone improve the yielding of prostate cancer screening?Can serum angiogenin be used to improve the diagnostic performance in prostate cancer screening?Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery.To biopsy or not to biopsy.Predictive factors of a successful testicular biopsy and subsequent clinical pregnancy.Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: results at 12-month follow-up.Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function.HUMAN SERUM ANGIOPOIETIN-1 (ANG-1) LEVELS ARE NOT ASSOCIATED TO PATHOLOGY DIAGNOSIS ON PROSTATE BIOPSYThe influence of different metabolic syndrome definitions in predicting vasculogenic erectile dysfunction: is there a role for the index of central obesity?Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment[Smoking Cessation after Bladder Cancer Diagnosis]
P50
Q33493614-C755BEB8-21A7-44A2-9DF4-E9FB802085B8Q33860372-0669AE5C-E40D-4A3B-915D-E09C48BC7D1DQ36471048-1B4DFFBD-29F2-4E32-BB45-87DC53E29460Q36924745-BF26A9B8-73EA-4A29-960F-B144C4CC3137Q37983231-BB87EAC8-759D-468C-A6D7-56D8EA9295D0Q38381455-FE1CDF03-E4B7-43D0-B2D4-DB4606C0A5C4Q39240698-3841D4EC-4E7F-459C-8AE3-B8F162EEBBAEQ40021871-324744CA-6355-4427-AC3C-016F92A81B8DQ40129272-9710B2F1-6C92-488D-A183-A2F3936C5E95Q47354765-3BED1748-234C-4496-ADEE-DF1DCBAF3725Q49888932-3F4065AF-D227-441E-88F5-524DECD21DF2Q51365746-DF512EFB-B9E8-4B29-A2AA-621EC9B18626Q51511125-2362F27F-4A8B-4871-9468-AB427DEBE257Q53163585-CFDBE22C-F45F-4E12-B9D4-C86132476FE3Q58228719-2B045DF0-B814-40D4-9167-0442DB8E7807Q58292080-483B40DC-C206-49AE-95A6-864C547C72ABQ82527018-6FD6D315-89A2-44F6-BCA9-75EBB9AD8DA6Q88215585-C5EF186A-A757-4FE2-A620-792C06C7FC55
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Francisco Botelho
@ast
Francisco Botelho
@en
Francisco Botelho
@es
Francisco Botelho
@nl
Francisco Botelho
@sl
type
label
Francisco Botelho
@ast
Francisco Botelho
@en
Francisco Botelho
@es
Francisco Botelho
@nl
Francisco Botelho
@sl
prefLabel
Francisco Botelho
@ast
Francisco Botelho
@en
Francisco Botelho
@es
Francisco Botelho
@nl
Francisco Botelho
@sl
P1053
B-5703-2014
P106
P21
P31
P3829
P496
0000-0002-6666-0883